FBIO Stock Overview
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Fortress Biotech, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.00 |
52 Week High | US$12.75 |
52 Week Low | US$1.24 |
Beta | 1.51 |
1 Month Change | 1.01% |
3 Month Change | -33.55% |
1 Year Change | -82.08% |
3 Year Change | -96.54% |
5 Year Change | -92.38% |
Change since IPO | -98.79% |
Recent News & Updates
Recent updates
There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise
Dec 29There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding
Aug 18Fortress to get NIH funding for trial of Triplex vaccine to prevent CMV in liver transplant patients
Aug 11David Jin is the new finance chief of Fortress Biotech
Jul 22Is Fortress Biotech (NASDAQ:FBIO) Using Debt Sensibly?
Jan 11Fortress Biotech (NASDAQ:FBIO) Has Debt But No Earnings; Should You Worry?
Sep 28Does Fortress Biotech (NASDAQ:FBIO) Have A Healthy Balance Sheet?
Jun 04Is Fortress Biotech (NASDAQ:FBIO) Using Too Much Debt?
Mar 04When Will Fortress Biotech, Inc. (NASDAQ:FBIO) Turn A Profit?
Feb 06Read This Before Buying Fortress Biotech, Inc. (NASDAQ:FBIO) Shares
Jan 11Fortress Biotech founded Cyprium's CUTX-101 nabs accelerated review for copper metabolism disorder
Dec 15Is Fortress Biotech, Inc. (NASDAQ:FBIO) Popular Amongst Insiders?
Dec 15Health Check: How Prudently Does Fortress Biotech (NASDAQ:FBIO) Use Debt?
Nov 19Fortress Biotech EPS misses by $0.02, misses on revenue
Nov 09Shareholder Returns
FBIO | US Biotechs | US Market | |
---|---|---|---|
7D | 1.5% | 0.9% | 0.4% |
1Y | -82.1% | 10.3% | 28.8% |
Return vs Industry: FBIO underperformed the US Biotechs industry which returned 10.3% over the past year.
Return vs Market: FBIO underperformed the US Market which returned 28.8% over the past year.
Price Volatility
FBIO volatility | |
---|---|
FBIO Average Weekly Movement | 14.0% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FBIO's share price has been volatile over the past 3 months.
Volatility Over Time: FBIO's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 187 | Lindsay Rosenwald | https://www.fortressbiotech.com |
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children.
Fortress Biotech, Inc. Fundamentals Summary
FBIO fundamental statistics | |
---|---|
Market cap | US$39.88m |
Earnings (TTM) | -US$78.31m |
Revenue (TTM) | US$61.97m |
0.6x
P/S Ratio-0.5x
P/E RatioIs FBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
FBIO income statement (TTM) | |
---|---|
Revenue | US$61.97m |
Cost of Revenue | US$155.48m |
Gross Profit | -US$93.51m |
Other Expenses | -US$15.20m |
Earnings | -US$78.31m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -4.26 |
Gross Margin | -150.89% |
Net Profit Margin | -126.36% |
Debt/Equity Ratio | -397.1% |
How did FBIO perform over the long term?
See historical performance and comparison